These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22764101)

  • 1. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
    Delage B; Luong P; Maharaj L; O'Riain C; Syed N; Crook T; Hatzimichael E; Papoudou-Bai A; Mitchell TJ; Whittaker SJ; Cerio R; Gribben J; Lemoine N; Bomalaski J; Li CF; Joel S; Fitzgibbon J; Chen LT; Szlosarek PW
    Cell Death Dis; 2012 Jul; 3(7):e342. PubMed ID: 22764101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
    Szlosarek PW; Steele JP; Nolan L; Gilligan D; Taylor P; Spicer J; Lind M; Mitra S; Shamash J; Phillips MM; Luong P; Payne S; Hillman P; Ellis S; Szyszko T; Dancey G; Butcher L; Beck S; Avril NE; Thomson J; Johnston A; Tomsa M; Lawrence C; Schmid P; Crook T; Wu BW; Bomalaski JS; Lemoine N; Sheaff MT; Rudd RM; Fennell D; Hackshaw A
    JAMA Oncol; 2017 Jan; 3(1):58-66. PubMed ID: 27584578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
    Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
    Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.
    Syed N; Langer J; Janczar K; Singh P; Lo Nigro C; Lattanzio L; Coley HM; Hatzimichael E; Bomalaski J; Szlosarek P; Awad M; O'Neil K; Roncaroli F; Crook T
    Cell Death Dis; 2013 Jan; 4(1):e458. PubMed ID: 23328665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20).
    Burrows N; Cane G; Robson M; Gaude E; Howat WJ; Szlosarek PW; Pedley RB; Frezza C; Ashcroft M; Maxwell PH
    Sci Rep; 2016 Mar; 6():22950. PubMed ID: 26972697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino Acid Uptake Measured by [
    Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
    Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
    [No Abstract]   [Full Text] [Related]  

  • 7. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
    McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
    BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
    Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
    Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.
    Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT
    Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment.
    Rogers LC; Kremer JC; Brashears CB; Lin Z; Hu Z; Bastos ACS; Baker A; Fettig N; Zhou D; Shoghi KI; Dehner CA; Chrisinger JSA; Bomalaski JS; Garcia BA; Oyama T; White EP; Van Tine BA
    Clin Cancer Res; 2023 Aug; 29(16):3189-3202. PubMed ID: 37339179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
    Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
    Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
    Allen MD; Luong P; Hudson C; Leyton J; Delage B; Ghazaly E; Cutts R; Yuan M; Syed N; Lo Nigro C; Lattanzio L; Chmielewska-Kassassir M; Tomlinson I; Roylance R; Whitaker HC; Warren AY; Neal D; Frezza C; Beltran L; Jones LJ; Chelala C; Wu BW; Bomalaski JS; Jackson RC; Lu YJ; Crook T; Lemoine NR; Mather S; Foster J; Sosabowski J; Avril N; Li CF; Szlosarek PW
    Cancer Res; 2014 Feb; 74(3):896-907. PubMed ID: 24285724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.
    Kim RH; Coates JM; Bowles TL; McNerney GP; Sutcliffe J; Jung JU; Gandour-Edwards R; Chuang FY; Bold RJ; Kung HJ
    Cancer Res; 2009 Jan; 69(2):700-8. PubMed ID: 19147587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
    Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
    Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
    Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
    Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
    Kuo MT; Savaraj N; Feun LG
    Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.
    Przystal JM; Hajji N; Khozoie C; Renziehausen A; Zeng Q; Abaitua F; Hajitou A; Suwan K; Want E; Bomalaski J; Szlosarek P; O'Neill K; Crook T; Syed N
    Cell Death Dis; 2018 Dec; 9(12):1192. PubMed ID: 30546006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.
    Bean GR; Kremer JC; Prudner BC; Schenone AD; Yao JC; Schultze MB; Chen DY; Tanas MR; Adkins DR; Bomalaski J; Rubin BP; Michel LS; Van Tine BA
    Cell Death Dis; 2016 Oct; 7(10):e2406. PubMed ID: 27735949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bench-to-Bedside Studies of Arginine Deprivation in Cancer.
    Field GC; Pavlyk I; Szlosarek PW
    Molecules; 2023 Feb; 28(5):. PubMed ID: 36903394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation.
    Singh PK; Deorukhkar AA; Venkatesulu BP; Li X; Tailor R; Bomalaski JS; Krishnan S
    Mol Cancer Ther; 2019 Dec; 18(12):2381-2393. PubMed ID: 31395686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.